Kawasaki Disease Clinical Trials 2023

Kawasaki Disease Clinical Trials 2023

Kawasaki Disease research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in kawasaki disease clinical trials today.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to kawasaki disease

What are the top hospitals conducting kawasaki disease research?

When it comes to cutting-edge clinical trials for Kawasaki disease, several hospitals are leading the way in research and treatment. In Valhalla, New york, the Mitchell Cairo hospital is at the forefront of innovation with one active trial for Kawasaki disease. This relatively rare condition primarily affects children and causes inflammation in blood vessels throughout the body. Similarly committed to finding solutions for this challenging illness, Columbia University and New York University also each have one ongoing trial dedicated to Kawasaki disease.

On the West Coast, the University of California San Diego has been making strides since its first recorded Kawasaki disease trial in 2012. With one current study underway and two completed trials under its belt, this institution is a vital player in advancing our knowledge and improving outcomes for patients living with this complex condition.

Meanwhile, Yale University School of Medicine's Infectious Diseases department has embraced their role by initiating an active clinical trial specifically targeting Kawasaki disease. While they do not yet hold any completed studies on record regarding this ailment; it’s encouraging that they are contributing to ongoing efforts to understand and combat this mysterious disorder.

These hospitals' dedication towards researching new treatments shines light on how important collaboration between medical institutions can be when tackling conditions as enigmatic as Kawasaki disease. Through these efforts, doctors hope to uncover crucial insights that will lead us closer toward better understanding and ultimately more effective management strategies against this perplexing illness affecting young lives worldwide

Which are the best cities for kawasaki disease clinical trials?

When it comes to clinical trials for Kawasaki disease, several cities are at the forefront of research and development. New york, New York leads with three active trials exploring treatments like Defibrotide and Pritelivir. Baltimore, Maryland follows closely behind with two ongoing studies focusing on interventions such as Pritelivir. Boston, Massachusetts and Miami, Florida also have two active trials each investigating treatments like Pritelivir. Additionally, Valhalla, New York contributes to the advancement of knowledge in this field with one active trial studying Defibrotide among others. These cities offer individuals affected by Kawasaki disease access to cutting-edge clinical trials that could potentially improve outcomes and enhance treatment options.

Which are the top treatments for kawasaki disease being explored in clinical trials?

Clinical trials are underway to explore potential treatments for Kawasaki disease. Currently, there is ongoing research on several promising options:

  • Defibrotide: A treatment being tested in one active trial dedicated to Kawasaki disease. It was first listed as a potential therapy in 2021.

  • Atorvastatin and anakinra: Another combination treatment under investigation with one active clinical trial specifically focusing on Kawasaki disease. This therapeutic approach was first introduced in 2017.

  • Doxycycline: In addition, doxycycline has also emerged as a potential treatment option and is currently being studied in one active clinical trial for Kawasaki disease. Its inclusion in the research began back in 2013.

These ongoing studies offer hope for new advancements that could potentially improve outcomes for those affected by this condition.

What are the most recent clinical trials for kawasaki disease?

Recent clinical trials have shed light on potential treatment options for Kawasaki disease, a condition primarily affecting children. One promising avenue of investigation is the use of defibrotide, which has entered Phase 2 trials as a potential therapeutic approach. Another study focuses on pritelivir and its efficacy in combating Kawasaki disease through Phase 3 trials conducted in the past. Furthermore, doxycycline has been explored as a possible intervention strategy during Phase 2 studies that took place previously. These recent clinical trials offer hope for improved management and care for individuals affected by this challenging condition.

What kawasaki disease clinical trials were recently completed?

Recently, there have been several notable clinical trials investigating treatments for Kawasaki disease. One such trial, sponsored by the National Institutes of Health (NIH), was completed in February 2021 and focused on evaluating the effectiveness of intravenous immunoglobulin therapy. Another study conducted by Boston Children's Hospital concluded in November 2020 and examined the use of anakinra as a potential treatment option. These completed trials contribute to advancing our understanding and management options for Kawasaki disease, offering hope to patients affected by this pediatric condition.